Affiliation:
1. School of Biomedical Engineering Faculty of Engineering The University of Sydney Sydney NSW 2006 Australia
2. School of Medical Sciences Faculty of Medicine and Health The University of Sydney Sydney NSW 2006 Australia
3. The University of Sydney Nano Institute The University of Sydney Sydney NSW 2006 Australia
4. The Charles Perkins Centre The University of Sydney Sydney NSW 2006 Australia
5. Heart Research Institute Newtown NSW 2042 Australia
6. School of Physics Faculty of Science The University of Sydney Sydney NSW 2006 Australia
Abstract
AbstractMicrofluidic systems have become integral for lab‐on‐a‐chip and organ‐on‐a‐chip applications across numerous disciplines. These systems, typically fabricated using polydimethylsiloxane (PDMS) chips on glass substrates, lack the bioactivity required for such applications. To overcome this, biomolecules are immobilized using either oxygen (O2) plasma treatment or chemical reagents like amino silanes. However, O2 plasma treatments are unstable and cannot covalently immobilize biomolecules, while wet‐chemistry approaches are toxic, time‐consuming, and expensive. A novel microfluidic platform that combines two plasma surface treatments: Plasma‐activated coating (PAC) and atmospheric pressure plasma jet (APPJ), to enable reagent‐free covalent immobilization of biomolecules is described here. These surface treatments, unlike O2 plasma, covalently immobilized fibronectin on PDMS and glass, and significantly improved endothelial cell attachment and proliferation. By combining PAC and APPJ, a hybrid microfluidic platform with equivalent bond strength to standard O2 plasma devices, but with significantly enhanced endothelial cell growth in and artery‐on‐a‐chip model, is developed. This platform is also amenable to high‐shear applications such as coronary shear, with endothelial cells aligning with flow, as seen in human arteries. By providing reagent‐free covalent immobilization of biomolecules within a microfluidic system, this technology has the potential to radically improve organ‐on‐a‐chip development as well as lab‐on‐a‐chip systems, point‐of‐care diagnostics, and sensors.
Funder
Australian Research Council
University of Sydney